Are we ready to take full advantage of patient‐derived tumor xenograft models?

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|24-27

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 24-27

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas

By  

Current Neuropharmacology, Vol. 15, Iss. 1, 2016-12 ,pp. : 98-103

Bentham Science Publishers

Access to resources Recommend Favorite

Patient-derived sarcoma xenografts for individual-patient selection of chemotherapy—ready for prime time?

By Wagner Andrew J.  

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 1917-1919

Blackwell Publishing

Access to resources Recommend Favorite

Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells

By  

Current Pharmaceutical Biotechnology, Vol. 15, Iss. 9, 2014-09 ,pp. : 839-846

Bentham Science Publishers

Access to resources Recommend Favorite

Assessing Cytotoxic Treatment Effects in Preclinical Tumor Xenograft Models

By Wu Jianrong  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 5, 2009-09 ,pp. : 755-762

Taylor & Francis Ltd

Access to resources Recommend Favorite

Assessment of Antitumor Activity for Tumor Xenograft Studies Using Exponential Growth Models

By Wu Jianrong  

Journal of Biopharmaceutical Statistics, Vol. 21, Iss. 3, 2011-05 ,pp. : 472-483

Taylor & Francis Ltd

Access to resources Recommend Favorite